drugset / Trial / NCT02033525
Mesenchymal Stromal Cells for Degenerative Meniscus Injury
Phase 1/2
Completed
20 enrolled
Blood and Tissue Bank of Catalonia
Hospital Universitari Quirón Dexeus · collabMinisterio de Sanidad, Servicios Sociales e Igualdad · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The present proposal has the objective to assess whether the addition of autologous ex vivo expanded mesenchymal stromal cells (XCEL-M-ALPHA) to the conventional meniscal injury rehabilitation program is contributing in creating the proper healing environment for the meniscus repair. For this purpose, 20 patients will be randomized (10 per group) to one of the two treatment arms (rehabilitation + xcel-m-alpha or rehabilitation alone) . The conduction of this clinical trial will, in addition of having the aim of improving the patient's quality of life, contribute to consolidate an emerging new type of therapy which is still under development.
Timeline
- Start
- 2014-01-31
- Primary completion
- 2017-05-02
- Completion
- 2017-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XCEL-M-ALPHA | Cell therapy | — | Other |
Indications
No indication recorded.